In our study, we have preliminarily demonstrated that AP‐1 inhibitors can be used to inhibit CEMIP expression, providing new insight into the mechanisms associated with upregulation of AP‐1 expression following knockdown of BMP6, which in turn causes CEMIP upregulation and thus exacerbates ventricular remodelling after MI. The gene discussed is FOS; the disease is myocardial infarction.